July 7, 2017
Tadaaki Taniguchi, Japan R&D Head, AstraZeneca AstraZeneca plans to go into the Japanese immuno-oncology market by first obtaining approval for its PD-L1 inhibitor durvalumab as a maintenance therapy in non-small cell lung cancer (NSCLC), leveraging that space to gradually raise...read more